Abstract

A scaffold hopping approach was exploited to guide the discovery of a series of pyridine derivatives as novel cyclin-dependent kinase (CDK2) inhibitors. These new compounds were designed, synthesized, and evaluated as CDK2 inhibitors. Most of the compounds showed potent inhibition against CDK2, and preliminary structure-activity relationship trends were revealed. A docking study on the most potent compound 6g implied the structural basis for potent CDK2 inhibition. All of the synthesized compounds were also evaluated for their cytotoxicity against the H522 and U87 cancer cell lines. The most potent and drug-like compound 6g was further tested against a normal cell line (L02), demonstrating that this compound is selectively toxic toward cancer cell lines. The results provide the foundation for further improving the potency of this series of compounds.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.